-
Ex-lawyer for pharma executive Shkreli convicted of aiding fraud scheme
-
'Pharma bro' Shkreli convicted of fraud in U.S. court, assails 'witch hunt'
-
Former Retrophin chairman says Martin Shkreli lied 'to my face'
-
U.S. prosecutors ask judge to silence Shkreli during trial
-
'Pharma bro' Shkreli suspended from Twitter for harassment
-
Ex-drug executive Shkreli to face U.S. fraud trial in June 2017
-
Witnesses in Shkreli case worried about retaliation: U.S. prosecutors
-
Ex-drug executive Shkreli has $40 million trading loss: U.S.
-
Ex-drug executive Shkreli hires lawyer to celebrities for fraud case
-
Exclusive: U.S. FTC probes Turing over drug prices, Shkreli's lawyer says
-
Drug exec Shkreli, lawmakers clash ahead of congressional hearing
-
KaloBios fires Shkreli as CEO
-
Martin Shkreli says securities fraud charges are 'baseless'
-
Turing Pharma names chairman to replace Shkreli as CEO
-
Big U.S. pharmacies square off on Daraprim supplies
-
Vilified for drug pricing, CEO Shkreli busted for securities fraud
-
Pershing Square, ValueAct are Top Hedge Funds at Risk of 'Squeeze' Amid Market Volatility - Symmetric
-
Pre-Open Stock Movers 5/30: (RTRX) (BIG) (NLNK) Higher; (BLOX) (BNNY) (EXPR) Lower (more...)
-
After-Hours Stock Movers 5/29: (RTRX) (OVTI) (CRM) Higher; (BLOX) (BNNY) (SPLK) Lower (more...)
-
SAC Capital Discloses 5.6% Stake in Retrophin (RTRX)

